People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Capstan Therapeutics, Inc. | — | Biotechnology | Series C | $227.0M | $881.9M | 2021 |
| Bright Peak Therapeutics, Inc. | — | Pharma | Series D+ | $196.5M | $1.0B | 2024 |
| Silverback Therapeutics, Inc. | — | Biotechnology | Series C | $139.3M | $3.2B | 2020 |
| Cleave Biosciences, Inc. | — | Biotechnology | Series B | $37.9M | $475.1M | 2016 |
| Synthorx, Inc. | — | Biotechnology | Series B | $34.7M | $1.1B | 2018 |
| Phenomix CORP | — | Biotechnology | Series A | $6.0M | $215.3M | 2010 |
Laura Shawver at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Laura Shawver on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Thompson | 3 | 16 |
| Jonathan Root | 2 | 16 |
| Asish Xavier | 1 | 18 |
| ANDREW LEVIN | 1 | 17 |
| Andrew Schwab | 1 | 16 |
| Michal Silverberg | 1 | 7 |
| Erez Chimovits | 1 | 7 |
| Josh Resnick | 1 | 7 |
| Tighe Reardon | 1 | 7 |
| Jay Lichter | 1 | 7 |
| Douglas Downs | 1 | 6 |
| Carol Gallagher | 1 | 6 |
| Court Turner | 1 | 6 |
| Timothy Smith | 1 | 5 |
| DENNIS HENNER | 1 | 5 |
| Peter A. Thompson | 1 | 5 |
| Brian Baker | 1 | 5 |
| Michael Baran | 1 | 4 |
| Nandita Shangari | 1 | 4 |
| Alexander Mayweg | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.